Union Budget 2026: ₹10,000 Crore Biopharma SHAKTI, 3 New NIPERs, and India’s Big Bet on Biologics and Biosimilars
India’s Budget 2026 announces a ₹10,000 crore Biopharma SHAKTI push to boost domestic production of biologics and biosimilars. The policy aims to strengthen CDSCO regulation, expand NIPERs, and build clinical trial capacity, signalling India’s shift from generic medicines to high-value biopharmaceutical innovation.
